Genetic Link Between Osteoprotegerin Gene and Prostate Cancer Risk
Author Information
Author(s): Narita Naofumi, Yuasa Takeshi, Tsuchiya Norihiko, Kumazawa Teruaki, Narita Shintaro, Inoue Takamitsu, Ma Zhiyong, Saito Mitsuru, Horikawa Yohei, Satoh Shigeru, Ogawa Osamu, Habuchi Tomonori
Primary Institution: Akita University School of Medicine
Hypothesis
Polymorphisms in the osteoprotegerin gene may act as genetic modifiers in the development and progression of prostate cancer.
Conclusion
The variant C allele of the 950 T/C polymorphism in the OPG promoter may protect against the progression of prostate cancer.
Supporting Evidence
- Patients with the TC and TT genotypes had a significantly increased risk of extraprostatic and metastatic disease.
- The presence of the T allele of the OPG 950 T/C polymorphism was an independent risk factor predicting survival.
- No significant differences in genotype frequencies were found between prostate cancer patients and controls for the 149 T/C polymorphism.
Takeaway
This study looked at how certain genes might affect the risk of getting advanced prostate cancer, finding that one gene variant could help protect against it.
Methodology
The study involved genotyping two polymorphisms in the osteoprotegerin gene among 361 prostate cancer patients and 195 controls.
Potential Biases
Potential selection bias in control group selection.
Limitations
The study's findings may not be generalizable beyond the Japanese population.
Participant Demographics
Native Japanese men, including 361 prostate cancer patients and 195 healthy controls.
Statistical Information
P-Value
0.031
Confidence Interval
1.072 – 4.341
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website